Intrinsic Value of S&P & Nasdaq Contact Us

EssilorLuxottica S.A. ESLOF OTC

Other OTC • Healthcare • Medical - Instruments & Supplies • FR • USD

SharesGrow Score
55/100
2/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

EssilorLuxottica S.A. (ESLOF) generated $5.29B in operating cash flow for fiscal year 2025. After capital expenditures of $1.52B, free cash flow was $3.76B.

Free cash flow margin was 13.2% of revenue. Cash conversion ratio was 2.29x, indicating earnings are backed by cash.

The company returned $546.8M in dividends and $375.86M in share buybacks to shareholders during the period.

Criteria supported by this page:

  • HEALTH (67/100, Partial) — cash generation is adequate but may not fully cover debt in stressed conditions
  • MOAT (81/100, Pass) — $3.76B (13.2% FCF margin) supports a durable competitive advantage
  • INCOME (45/100) — Cash conversion ratio was 2.29x confirms earnings are backed by real cash flow

Overall SharesGrow Score: 55/100 with 2/7 criteria passed.

SharesGrow 7-Criteria Score
55/100
SG Score
View full scorecard →
VALUE
15/100
Price-to-Earnings & upside
→ Valuation
FUTURE
20/100
Analyst consensus
→ Forecast
PAST
100/100
→ Income
~
HEALTH
67/100
Debt-to-Equity & liquidity
Proven by this page
MOAT
81/100
Proven by this page
~
GROWTH
55/100
→ Income
~
INCOME
45/100
→ Income
EssilorLuxottica S.A. Cash Flow History
Metric TTM FY2025 FY2024 FY2023 FY2022
Operating Cash Flow $10.16B$5.29B$4.87B$4.86B$4.78B
Capital Expenditure $-3.05B$-1.52B$-1.52B$-1.53B$-1.57B
Free Cash Flow $7.12B$3.76B$3.35B$3.33B$3.21B
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message